Astellas Pharma US, Inc. Selects Dendrite for Sample Compliance Solutions; Dendrite's Robust and Intuitive Compliance Solutions
14 Août 2006 - 2:00PM
Business Wire
Dendrite International, Inc., (NASDAQ: DRTE) a leading provider of
pharmaceutical industry solutions, today announced that Astellas
Pharma US, Inc., a pharmaceutical company dedicated to improving
the health of populations around the world, signed a three-year
contract to outsource its sample accountability and compliance
processes to Dendrite. Dendrite's market-leading Compliance
Solutions division will manage Astellas Pharma US Inc.'s compliance
requirements using several components of its comprehensive solution
offering. This includes reconciliation services, web-based
reporting and trending services, inventory and audit services, and
sales representative closeouts, enabling the Astellas' US sales
force of more than 500 sales representatives to remain compliant
with Prescription Drug Marketing Act (PDMA) requirements. "Dendrite
came out on top in our evaluation of companies that could meet our
immediate and long term needs for sample management and compliance.
Their reputation and capabilities are strong, and we're confident
they will continue to provide value as we progress in our
relationship," said Kathy Pettinato, associate director Sampling
Operations at Astellas. "Our compliance solutions are designed to
decrease the administrative burden associated with the
accountability of drug samples while enhancing compliance levels,"
said Bill Buzzeo, vice president and general manager Dendrite
Compliance Solutions division. "As Astellas continues to grow, it
is critical for them to have the most sophisticated, yet highly
intuitive sample accountability and compliance solutions
available." About Dendrite Founded in 1986, Dendrite International
(NASDAQ: DRTE) enables sales, marketing, clinical and compliance
solutions for the global pharmaceutical industry. The Company's
clients are located in more than 50 countries and include the
world's top 20 pharmaceutical companies. For more information,
please visit www.dendrite.com. About Astellas Pharma US, Inc.
Astellas Pharma US, Inc., located in Deerfield, Illinois, is a US
affiliate of Tokyo-based Astellas Pharma Inc., Astellas is a
pharmaceutical company dedicated to improving the health of people
around the world through the provision of innovative and reliable
pharmaceutical products. The organization is committed to becoming
a global pharmaceutical company by combining outstanding R&D
and marketing capabilities and continuing to grow in the world
pharmaceutical market. For more information about Astellas Pharma
US, Inc., please visit our website at www.astellas.com/us. Note:
Dendrite is a registered trademark of Dendrite International, Inc.
This document may contain forward-looking statements that may be
identified by such forward-looking terminology as "expect,"
"believe," "anticipate," "will," "intend," "plan," "target,"
"outlook," "guidance," and similar statements or variations. Such
forward-looking statements are based on our current expectations,
estimates, assumptions and projections and involve significant
risks and uncertainties, including risks which may result from our
dependence on the pharmaceutical industry; fluctuations in
quarterly revenues due to lengthy sales and implementation cycles
for certain of our solutions; our fixed expenses in relation to
fluctuating revenues and variations in customers' budget cycles;
dependence on certain major customers; changes in demand for our
products and services attributable to any weakness experienced in
the economy or mergers, acquisitions and consolidations in the
pharmaceutical industry; successful and timely development and
introduction of new products and versions; rapid technological
changes; increased competition; international operations;
integrating the entities we acquire; our ability to effectively
manage our growth; the protection of our proprietary technology;
our ability to compete in the Internet-related products and
services market; the continued demand for Internet-related products
and services; the ability of our third party vendors to respond to
technological change; our ability to maintain our relationships
with third-party vendors; less favorable than anticipated results
from strategic relationships; dependence of data solutions on
strategic relationships; events which may affect the U.S. and world
economies; and catastrophic events which could negatively affect
our information technology infrastructure. Other important factors
that should be reviewed and carefully considered are included in
the company's 10-K, 10-Qs, and other reports filed with the SEC.
Actual results may differ materially. The company assumes no
obligation for updating any such forward-looking statements to
reflect actual results, changes in assumptions or other changes
affecting such forward-looking statements.
Dendrite (NASDAQ:DRTE)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Dendrite (NASDAQ:DRTE)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Dendrite International (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Dendrite International, Inc.